quality of life

News

Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide

Janet Fricker
6 October 2020

In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and enzalutamide, reports the latest analysis of the CARD trial (Fizazi…

View Post

Cancerworld is published by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.

Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide

Study helps solve the puzzle of checkpoint inhibitor myocarditis

Smoking cessation fundamental to first-line cancer care

Large-scale whole genome sequencing identifies six new cancer susceptibility/ resistance genes

Lessons in nature: knowledge of exceptional animals could help tackle human cancers

Breast cancer treatments may accelerate ageing

Florida shows cancer outcomes are better where healthcare reflects local cultures

Somewhere to care for Gaza’s cancer patients: the head of the service calls for a ‘field hospital’

Surgery or radiotherapy? How the pandemic provide an opening to gather the evidence that patients need

Would you follow us ?

Assia Konsoulova: improving Bulgaria’s cancer system one oasis at a time

‘I feel guilty sometimes’: a young carer reflects on three years of a losing battle to save his mum

Voices from Gaza: caught between conflict and cancer

MENU